The global AI-based clinical trials solution provider market size is accounted at USD 2.88 billion in 2025 and is forecasted to hit around USD 17.40 billion by 2034, representing a CAGR of 22.13% from 2025 to 2034. The North America market size was estimated at USD 1.04 billion in 2024 and is expanding at a CAGR of 22.23% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: AI-based Clinical Trials Solution Provider Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. AI-based Clinical Trials Solution Provider Market, by Clinical Trial Phase, 2025-2034
8.1.1 Phase-I
8.1.1.1. Market Revenue and Forecast (2022-2034)
8.1.2. Phase-II
8.1.2.1. Market Revenue and Forecast (2022-2034)
8.1.3. Phase-III
8.1.3.1. Market Revenue and Forecast (2022-2034)
9.1. AI-based Clinical Trials Solution Provider Market, by Therapeutic Applications, 2025-2034
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast (2022-2034)
9.1.2. CVD
9.1.2.1. Market Revenue and Forecast (2022-2034)
9.1.3. Neurological Diseases or Conditions
9.1.3.1. Market Revenue and Forecast (2022-2034)
9.1.4. Metabolic Diseases
9.1.4.1. Market Revenue and Forecast (2022-2034)
9.1.5. Infectious Diseases
9.1.5.1. Market Revenue and Forecast (2022-2034)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2022-2034)
10.1. AI-based Clinical Trials Solution Provider Market, by End-use, 2025-2034
10.1.1. Pharmaceutical Companies
10.1.1.1. Market Revenue and Forecast (2022-2034)
10.1.2. Academia
10.1.2.1. Market Revenue and Forecast (2022-2034)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2022-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.1.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.1.3. Market Revenue and Forecast, by End-use (2022-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.1.4.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.1.4.3. Market Revenue and Forecast, by End-use (2022-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.1.5.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.1.5.3. Market Revenue and Forecast, by End-use (2022-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.2.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.2.3. Market Revenue and Forecast, by End-use (2022-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.2.4.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.2.4.3. Market Revenue and Forecast, by End-use (2022-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.2.5.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.2.5.3. Market Revenue and Forecast, by End-use (2022-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.2.6.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.2.6.3. Market Revenue and Forecast, by End-use (2022-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.2.7.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.2.7.3. Market Revenue and Forecast, by End-use (2022-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.3.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.3.3. Market Revenue and Forecast, by End-use (2022-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.3.4.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.3.4.3. Market Revenue and Forecast, by End-use (2022-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.3.5.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.3.5.3. Market Revenue and Forecast, by End-use (2022-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.3.6.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.3.6.3. Market Revenue and Forecast, by End-use (2022-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.3.7.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.3.7.3. Market Revenue and Forecast, by End-use (2022-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.4.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.4.3. Market Revenue and Forecast, by End-use (2022-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.4.4.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.4.4.3. Market Revenue and Forecast, by End-use (2022-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.4.5.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.4.5.3. Market Revenue and Forecast, by End-use (2022-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.4.6.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.4.6.3. Market Revenue and Forecast, by End-use (2022-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.4.7.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.4.7.3. Market Revenue and Forecast, by End-use (2022-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.5.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.5.3. Market Revenue and Forecast, by End-use (2022-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.5.4.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.5.4.3. Market Revenue and Forecast, by End-use (2022-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Clinical Trial Phase (2022-2034)
11.5.5.2. Market Revenue and Forecast, by Therapeutic Applications (2022-2034)
11.5.5.3. Market Revenue and Forecast, by End-use (2022-2034)
12.1. Unlearn.AI
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Saama Technologies
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Antidote Technologies
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Deep6.ai
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Innoplexus
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Intelligence
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Median Technologies
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. SymphonyAI
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. BioAge Labs, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. AiCure
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample